Pipeline Review on Rotavirus Infections - H1 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Rotavirus Infections - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical, Discovery and Unknown stages comprises 1, 3, 1, 1 and 1 molecules, respectively.

Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  

Key Topics Covered:

• Introduction
• Report Coverage
• Rotavirus Infections - Overview
• Rotavirus Infections - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Rotavirus Infections - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Rotavirus Infections - Companies Involved in Therapeutics Development
• Rotavirus Infections - Drug Profiles
• (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
• (rotavirus (virus like particle) + typhiod) vaccine - Drug Profile
• MDG-5625 - Drug Profile
• poliomyelitis vaccine + rotavirus vaccine - Drug Profile
• Rotavac-5C - Drug Profile
• rotavirus (pentavalent) vaccine - Drug Profile
• rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile
• rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile
• rotavirus [serotypes A1, A2, A3, A4] (tetravalent) vaccine - Drug Profile
• rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
• rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
• rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile
• rotavirus [serotypes G1, G2, G3, G4, P1(8)] (pentavalent) vaccine - Drug Profile
• rotavirus vaccine - Drug Profile
• rotavirus vaccine - Drug Profile
• rotavirus vaccine - Drug Profile
• RV-3BB - Drug Profile
• RV-625 - Drug Profile
• UMN-103 - Drug Profile
• Rotavirus Infections - Dormant Projects
• Rotavirus Infections - Product Development Milestones
• Featured News & Press Releases
• Jun 03, 2019: Rotavirus vaccine (Rotarix): patient group direction (PGD) template
• Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification
• Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus
• Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate
• Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus
• Apr 26, 2012: GSK's Rotarix To Be Introduced In Ghana
• Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan
• May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix
• Oct 15, 1999: Wyeth Lederle Vaccines Voluntarily Withdraws from the Market its Rotavirus Vaccine RotaShield
• Aug 31, 1998: Wyeth-Ayerst Receives FDA Licensure for RotaShield; First Vaccine for Use in the Prevention of Rotavirus
• Appendix

Companies Mentioned

• Aridis Pharmaceuticals Inc
• Beijing Minhai Biotechnology Co Ltd
• Bharat Biotech Ltd
• Chongqing Zhifei Biological Products Co Ltd
• GlaxoSmithKline Plc
• Hilleman Laboratories Pvt Ltd
• Medicago Inc
• Micron Biomedical Inc
• Pfizer Inc
• Serum Institute of India Ltd
• UMN Pharma Inc
• Yisheng Biopharma Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/68cmya